CY1106771T1 - Φαρμακευτικη συνθεση η οποια χρησιμοποιειται για τον ελεγχο της γλυκοζης του αιματος σε ασθενεις με διαβητη τυπου 2 - Google Patents

Φαρμακευτικη συνθεση η οποια χρησιμοποιειται για τον ελεγχο της γλυκοζης του αιματος σε ασθενεις με διαβητη τυπου 2

Info

Publication number
CY1106771T1
CY1106771T1 CY20071101008T CY071101008T CY1106771T1 CY 1106771 T1 CY1106771 T1 CY 1106771T1 CY 20071101008 T CY20071101008 T CY 20071101008T CY 071101008 T CY071101008 T CY 071101008T CY 1106771 T1 CY1106771 T1 CY 1106771T1
Authority
CY
Cyprus
Prior art keywords
patients
diabetes
blood glucose
type
combination
Prior art date
Application number
CY20071101008T
Other languages
English (en)
Inventor
José Manuel Francisco LARA OCHOA
Original Assignee
Laboratorios Silanes, S.A. De C.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27607097&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1106771(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratorios Silanes, S.A. De C.V. filed Critical Laboratorios Silanes, S.A. De C.V.
Publication of CY1106771T1 publication Critical patent/CY1106771T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Abstract

Φαρμακευτικές συνθέσεις των δραστικών ουσιών γλυμπεπυριδίου με ένζυμο μετασχηματισμού ή τα άλατα αυτής όπως υδροχλωρίδιο, σουκκινικό άλας, φουμαρικό άλας, κλπ είναι χρήσιμες για τον έλεγχο της γλυκόζης του αίματος σε ασθενείς με διαβήτη τύπου 2. Προκειμένου να αποδειχθεί η αποτελεσματικότητα του συνδυασμού, πραγματοποιήθηκαν κλινικές μελέτες οι οποίες κατέδειξαν την ύπαρξη όχι μόνο μιας επιπρόσθετης δράσης, αλλά επίσης μιας συνεργατικής δράσης των δυο φαρμάκων σε σύγκριση με μονοθεραπεία με τη χρησιμοποίηση ενός από τα φάρμακα που χρησιμοποιούνται στο συνδυασμό. Κατά συνέπεια, ο συνδυασμός μπορεί να χρησιμοποιηθεί σαν μια αποτελεσματική και ασφαλής θεραπεία για τον έλεγχο της γλυκόζης του αίματος σε ασθενείς με διαβήτη τύπου 2, με τη χρησιμοποίηση διαφορετικών αναλογιών των δραστικών ουσιών σε συνδυασμούς κατάλληλους για τις ανάγκες των διαφορετικών ασθενών.
CY20071101008T 2002-01-25 2007-07-30 Φαρμακευτικη συνθεση η οποια χρησιμοποιειται για τον ελεγχο της γλυκοζης του αιματος σε ασθενεις με διαβητη τυπου 2 CY1106771T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2002/000003 WO2003061643A1 (es) 2002-01-25 2002-01-25 Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2

Publications (1)

Publication Number Publication Date
CY1106771T1 true CY1106771T1 (el) 2012-05-23

Family

ID=27607097

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101008T CY1106771T1 (el) 2002-01-25 2007-07-30 Φαρμακευτικη συνθεση η οποια χρησιμοποιειται για τον ελεγχο της γλυκοζης του αιματος σε ασθενεις με διαβητη τυπου 2

Country Status (11)

Country Link
US (2) US9045438B2 (el)
EP (1) EP1482919B1 (el)
AT (1) ATE361065T1 (el)
BR (1) BRPI0502691A (el)
CY (1) CY1106771T1 (el)
DE (1) DE60219963T2 (el)
DK (1) DK1482919T3 (el)
ES (1) ES2284829T3 (el)
MX (1) MXPA04007183A (el)
PT (1) PT1482919E (el)
WO (1) WO2003061643A1 (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1482919E (pt) 2002-01-25 2007-07-25 Silanes Sa De Cv Lab Composição farmacêutica que é utilizada para controlar a glucose no sangue de doentes com diabetes de tipo 2.
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
MXPA05009633A (es) * 2005-09-08 2007-03-07 Silanes Sa De Cv Lab Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada.
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
US20120095059A1 (en) * 2010-04-13 2012-04-19 Jorge Luis Rosado Compositions and Methods for Treating Type II Diabetes and Related Disorders
MX339374B (es) * 2011-04-29 2016-05-13 Inst De Investigación En Química Aplic S A De C V Cocristales ionicos con base en metformina.
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
EP2712628B1 (en) * 2012-09-28 2016-08-10 Shanta Banerjee Composition for use as a medicine or dietetic food, in particular in the prevention and/or treatment of Diabetes and diabetes associated diseases
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
EP3050023B1 (en) 2014-10-27 2021-08-25 Aseko, Inc. Subcutaneous outpatient management
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
CA2993275C (en) 2015-08-20 2022-06-21 Aseko, Inc. Diabetes management therapy advisor

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3072527A (en) * 1959-07-01 1963-01-08 Horner Frank W Ltd Use of tolbutamide in the treatment of acne
JP3465247B2 (ja) * 1992-12-28 2003-11-10 アベンティス ファーマ株式会社 動脈硬化症の予防および治療剤
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
US6348469B1 (en) * 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
IT1276130B1 (it) 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
JP4278863B2 (ja) * 1997-12-08 2009-06-17 ブリストル−マイヤーズ スクイブ カンパニー メトホルミンの新規塩および方法
SI0974356T1 (en) * 1998-07-15 2003-12-31 Merck Sante Tablets comprising a combination of metformin and glibenclamide
DE19860698A1 (de) 1998-12-30 2000-07-06 Hexal Ag Neue pharmazeutische Zusammensetzung
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
US6499984B1 (en) * 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation
JP2004505913A (ja) * 2000-08-07 2004-02-26 ランバクシー　シグネチャー，エルエルシー メトフォルミンの液体処方
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
PT1482919E (pt) 2002-01-25 2007-07-25 Silanes Sa De Cv Lab Composição farmacêutica que é utilizada para controlar a glucose no sangue de doentes com diabetes de tipo 2.
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
EP1562607A1 (en) 2002-11-15 2005-08-17 Ranbaxy Laboratories, Ltd. Pharmaceutical dosage forms of biguanide-sulfonylurea combinations
MXPA05009633A (es) * 2005-09-08 2007-03-07 Silanes Sa De Cv Lab Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada.

Also Published As

Publication number Publication date
DE60219963T2 (de) 2008-02-07
US20050239887A1 (en) 2005-10-27
ATE361065T1 (de) 2007-05-15
US20160051511A1 (en) 2016-02-25
MXPA04007183A (es) 2006-03-06
ES2284829T3 (es) 2007-11-16
PT1482919E (pt) 2007-07-25
EP1482919A1 (en) 2004-12-08
WO2003061643A1 (es) 2003-07-31
DK1482919T3 (da) 2007-07-30
DE60219963D1 (de) 2007-06-14
BRPI0502691A (pt) 2006-03-07
US9045438B2 (en) 2015-06-02
EP1482919B1 (en) 2007-05-02

Similar Documents

Publication Publication Date Title
CY1106771T1 (el) Φαρμακευτικη συνθεση η οποια χρησιμοποιειται για τον ελεγχο της γλυκοζης του αιματος σε ασθενεις με διαβητη τυπου 2
CY1116463T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
BG106825A (en) Substituted oxazolidinones and their use in the field of blood coagulation
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
CY1110019T1 (el) Συνδυασμενη θεραπεια με υποκατεστημενες οξαζολιδινονες
CY1115580T1 (el) Συνθεση και αντι-ιικη δραστηριοτητα των υποκατεστημενων παραγωγων αζαϊνδολοοξικης πιπεραζινης
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
DE60336664D1 (de) Nichtnukleosidische reverse-transkriptase-hemmer
EA200870086A1 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для лечения маниакального синдрома и биполярного расстройства
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
CY1113404T1 (el) Μεθοδος αντιμετωπισης ή προληψης της πολυ- οργανικης ανεπαρκειας
UY27018A1 (es) Derivados de la pirimidina
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
NO20053876D0 (no) Karbonylaminosubstituerte acylfenylurederivater, fremgangsmate for deres fremstilling samt anvendelse derav
PE20030277A1 (es) Composicion farmaceutica que comprende 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y l-dopa
BR112023000229A2 (pt) Composto, composição farmacêutica, e, peptídeo
NO20030021D0 (no) Heterosykliske forbindelser som er inhibitorer for enzymet DPP-IV
DE60303149D1 (de) Salz von morphin-6-glucuronid
SE0203817D0 (sv) New composition
BR0317292A (pt) Derivados de amida de ácido antranìlico e seu uso farmacêutico
BR0314647A (pt) Uso de derivados de 4-piridilmetil-ftalazina para a preparação de um medicamento para o tratamento de sìndromes melodisplásicas
BR0215498A (pt) Composição farmacêutica compreendendo uma glitazona e um ácido 4-oxobutanóico e o seu uso para o tratamento de diabetes
UY26502A1 (es) Oxazolidinonas substituidas y su uso